Physician profile
Arwen E Podesta
NPI 1194914598
$466,474.11
in general payments reported to CMS, 2019-2025
28 companies · $169K in 2025
The $169K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $24K · 2021: $16K · 2022: $44K · 2023: $58K · 2024: $101K · 2025: $169K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $94K · Honoraria: $93K · Consulting Fee: $85K · Travel and Lodging: $48K · Food and Beverage: $8,566 · Education: $98.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $93,627.00 |
| Honoraria | $93,092.00 |
| Consulting Fee | $85,142.00 |
| Travel and Lodging | $47,647.92 |
| Food and Beverage | $8,565.71 |
| Education | $98.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $145,808.56 | 2019-2025 | Vivitrol, Vivitrol, Aristada |
| Indivior INC. | $101,513.95 | 2019-2025 | Sublocade |
| Braeburn INC. | $64,929.35 | 2023-2025 | Brixadi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46,459.44 | 2024-2025 | Rejoyn, Abilify Mycite |
| Axsome Therapeutics, INC. | $43,541.96 | 2024-2025 | Auvelity, Sunosi |
| Abbvie INC. | $20,511.15 | 2023-2025 | |
| Pear Therapeutics (US), INC. | $16,809.95 | 2021-2022 | |
| Eli Lilly and Company | $9,888.23 | 2025 | |
| Mdd US Operations, LLC | $5,511.70 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,350.00 | 2025 | |
| Sandoz INC. | $3,318.75 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $1,614.76 | 2022-2023 | |
| Orexo US, INC. | $1,543.47 | 2019-2022 | |
| Kaleo, INC. | $650.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $291.26 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $164.31 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $160.93 | 2022-2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company Ltd. | $66.10 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $59.07 | 2020-2021 | |
| Shire North American Group INC | $54.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $53.87 | 2023-2025 | Spravato |
| Jazz Pharmaceuticals INC. | $41.70 | 2021 | |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $28.00 | 2023 | Qelbree |
| Almatica Pharma LLC | $21.42 | 2021 | |
| Eisai INC. | $15.33 | 2022 | |
| Adlon Therapeutics L.P. | $15.11 | 2020 | |
| Acadia Pharmaceuticals INC | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arwen Podesta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.